Product Details

Verythro Oral Suspension meets pharmacopoeial standards for the treatment of bacterial infections. Specifically, each 5ml delivers Erythromycin Ethylsuccinate equivalent to 250mg Erythromycin. As a result, it offers reliable macrolide antibiotic coverage in a convenient liquid formulation, particularly for patients who cannot tolerate penicillin-based therapy.

The suspension contains:

• Erythromycin Ethylsuccinate (equivalent to Erythromycin 250mg per 5ml) – A macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Consequently, it exerts bacteriostatic activity against a range of gram-positive organisms and certain atypical pathogens.

Physicians prescribe Verythro for the treatment of respiratory tract infections, skin and soft tissue infections, and certain sexually transmitted infections, particularly in patients with penicillin allergy. In addition, its oral suspension format supports easy administration in children and patients who have difficulty swallowing tablets or capsules. Because of this profile, Verythro suits paediatric practices, general practice, and hospital settings managing bacterial infections in penicillin-sensitive patients.

Key Features:

• Overall, this formulation guarantees pharmaceutical-grade purity
• Additionally, the oral suspension format supports easy, convenient dosing for children
• Furthermore, each 5ml delivers precise, validated dosage accuracy at 250mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, amber bottle packaging protects the light-sensitive formulation
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies